Virus-like particles coexpressing the PreF and Gt antigens of respiratory syncytial virus confer protection in mice

Nanomedicine (Lond). 2022 Jul;17(17):1159-1171. doi: 10.2217/nnm-2022-0082. Epub 2022 Sep 14.

Abstract

Aims: The purpose of this study was to assess the protective efficacy of virus-like particles (VLPs) co-expressing the pre-fusogenic (PreF) and G protein with tandem repeats (Gt) antigens of respiratory syncytial virus (RSV) in mice. Materials & methods: VLP constructs expressing PreF, Gt or both were used to immunize mice, and the protective efficacies were evaluated using antibody responses, neutralizing antibody titers, T-cell responses, histopathological assessment and plaque assay. Results: PreF+Gt VLP immunization elicited strong RSV-specific antibody responses and pulmonary T-cell responses that contributed to lessening virus titer and inflammation. Conclusion: Our findings suggest that coexpressing PreF and Gt antigens elicits better protection than either one alone. This combinatorial approach could assist in future RSV vaccine development.

Keywords: mice; protection; respiratory syncytial virus; vaccine; virus-like particle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Mice
  • Mice, Inbred BALB C
  • Respiratory Syncytial Virus Infections* / prevention & control
  • Respiratory Syncytial Virus Vaccines*
  • Respiratory Syncytial Virus, Human* / genetics
  • Viral Fusion Proteins / genetics

Substances

  • Viral Fusion Proteins
  • Antibodies, Neutralizing
  • Respiratory Syncytial Virus Vaccines
  • Antibodies, Viral